section name header

Pronunciation

mox-i-FLOX-a-sin audio

Indications

REMS

Action

Therapeutic Effects:

Spectrum:

Pharmacokinetics

Absorption: Well absorbed (90%) following oral administration.

Distribution: Widely distributed; tissue concentrations may exceed plasma concentrations.

Metabolism/Excretion: Mostly metabolized by the liver; 20% excreted unchanged in urine, 25% excreted unchanged in feces.

Half-life: 12 hr.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: AORTIC ANEURYSM/DISSECTION, TORSADE DE POINTES, QT interval prolongation.

Derm: STEVENS-JOHNSON SYNDROME, photosensitivity.

Endo: hyperglycemia, hypoglycemia.

GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), diarrhea, nausea, abdominal pain, dyspepsia, liver enzymes, vomiting.

MS: arthralgia, myalgia, tendinitis, tendon rupture.

Neuro: peripheral neuropathy , ELEVATED INTRACRANIAL PRESSURE (INCLUDING PSEUDOTUMOR CEREBRI), SEIZURES, SUICIDAL THOUGHTS, agitation, anxiety, confusion, depression, dizziness, hallucinations, headache, insomnia, nightmares, paranoia, toxic psychosis, tremor.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Interactions

Drug-Drug:

Route/Dosage

Implementation

US Brand Names

Avelox

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: Fluoroquinolones

Availability

(Generic available)

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POwithin 1 hr1–3 hr24 hr
IVrapidend of infusion24 hr

Assessment

Lab Test Considerations:

Pot. Nursing Diagnoses

Patient/Family Teaching

Evaluation/Desired Outcomes

Code

NDC Code*